Assessment of health-related quality of life in patients with heart failure: a cross-sectional study in Saudi Arabia

Alharbi, Muslet; Alharbi, Fahad J.; AlTuwayjiri, Abdullah; Alharbi, Yaqoub; Alhofair, Yazeed; Alanazi, Ahmed; AlJlajle, Faisal; Khalil, Rehana; Al‐Wutayd, Osama

doi:10.1186/s12955-022-02040-7

Cited by 17 publications

(16 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alharbi et al in Saudi Arabia [ 16 ] and Rodríguez-Artalejo et al in Spain [ 17 ] also noted that the RP domain had the lowest scores, consistent with our study. Heart failure is characterized by a cluster of symptoms and signs resulting from structural or functional cardiac abnormalities [ 18 ].…”

Section: Discussionsupporting

confidence: 92%

“…Upon conducting subgroup analysis based on variables such as age, gender, or LVEF, no statistically significant differences were observed in PCS, MCS, and overall HRQoL scores. [16] and Rodríguez-Artalejo et al in Spain [17] also noted that the RP domain had the lowest scores, consistent with our study. Heart failure is characterized by a cluster of symptoms and signs resulting from structural or functional cardiac abnormalities [18].…”

Section: Discussionsupporting

confidence: 92%

“…Participants were classified into four groups depending on their HRQoL scores. Scores from 0 to 25 were considered very low, scores from 25 to < 50 were low, scores from 50 to < 75 were moderate, and scores between 75 to 100 were high [ 15 , 16 ]. The physical component score is calculated by summing scores from four domains: PF (10 items), RP (four items), BP (two items), and GH (five items).…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Assessment of Health-Related Quality of Life in Patients with Chronic Heart Failure: A Cross-Sectional Study in Vietnam

Truong,

Nguyen,

Tran

et al. 2023

Cureus

View full text Add to dashboard Cite

Heart failure is currently a global health issue, imposing a burden on disease prevalence and mortality rates for patients, while simultaneously impacting the quality of life for affected individuals. Data on assessing the health-related quality of life (HRQoL) of patients with chronic heart failure in developing countries, including Vietnam, is still limited. This study was conducted with the aim of describing the quality of life of patients with chronic heart failure in Vietnam. MethodsThis cross-sectional investigation enrolled 140 chronic heart failure outpatients, utilizing a convenience sample at Hai Duong Province Hospital, Vietnam, spanning from December 2021 to April 2022. Essential patient variables encompassing age, gender, and heart failure duration were gathered. Surveying of patients took place at the outpatient clinic during chronic heart failure follow-up visits using the 36-Item Short Form Health Survey (SF-36) questionnaire. The SF-36 comprises eight dimensions: (1) Physical functioning, (2) Role limitations due to physical health, (3) Bodily pain, (4) General health perceptions, (5) Vitality, (6) Social role functioning, (7) Role limitations due to emotional health, and (8) Mental health. Component analysis of the SF-36 revealed two distinct concepts: a physical component summary (PCS) reflecting the physical aspect and a mental component summary (MCS) reflecting the mental aspect. ResultsThe research involved 140 participants diagnosed with chronic heart failure, having a median age of 59 years (interquartile range (IQR): 52-63). Among them, 61.4% were male, and 50% exhibited reduced left ventricular ejection fraction (LVEF) (≤ 40%). The role limitations due to the physical health domain indicated the lowest score, registering a median value of 0 (IQR 0-25). Domains with median scores below the 25-point threshold encompassed role limitations due to physical health (0 points). Those with scores ranging from 25 to 49 points constituted general health perceptions (25 points), role limitations due to emotional health (33.3 points), vitality (45 points), and mental health (48 points). Bodily pain and social role functioning achieved median scores at a moderate level (50-74 points), scoring 62 and 62.5 points, respectively. The overall HRQoL score on the SF-36 scale was 45.2 (IQR: 32.1-58.7) points. Median scores for the PCS and MCS were 44.3 (IQR: 30.5-52) and 47.0 (IQR: 32.6-65.4), respectively. No statistically significant differences in PCS and MCS scores were observed when subgroup analysis was performed based on variables like age, gender, or LVEF. However, in the vitality domain, female patients exhibited a significantly lower median score than male patients (p-value = 0.046). In the physical functioning domain, individuals aged ≥ 60 had lower median scores than those aged < 60 years (p = 0.022). Additionally, the group with LVEF ≤ 40% had lower median scores compared to the group with LVEF > 40% (p = 0.038) in role limitations due to emotional health domain. ConclusionIn Vietnam, the HRQoL i...

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 92%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Assessment of Health-Related Quality of Life in Patients with Chronic Heart Failure: A Cross-Sectional Study in Vietnam

Truong,

Nguyen,

Tran

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

“…[5] This phenomenon can be attributed to the increasing prevalence of obesity and significant socioeconomic transformations that have resulted in the uptake of detrimental behaviors, including the consumption of high-calorie foods, tobacco use, and insufficient physical activity. [17] A systematic review of real-world observational studies of Sac/Val in patients with HFrEF also reported variations in the baseline characteristics between the studies compared with PARADIGM-HF. [18] Similar to our study, patients included in the systematic review had a higher incidence of DM and more patients were on MRA than in the PARADIGM-HF study.…”

Section: Discussionmentioning

confidence: 99%

Real-world analysis of integration of sacubitril/valsartan into clinical practice in Saudi Arabia

Badreldin,

Korayem,

Alenazy

et al. 2023

Medicine

View full text Add to dashboard Cite

Despite the demonstrated advantages of angiotensin receptor/neprilysin inhibitors in the management of heart failure, the pivotal Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure (PARADIGM-HF) trial, which explored this class of medications, did not include individuals from Saudi Arabia. Recognizing that different nations and ethnic groups may exhibit unique characteristics, this study aimed to compare the demographics and outcomes of patients in Saudi Arabia who received sacubitril/valsartan (Sac/Val) with those enrolled in the PARADIGM-HF trial. In this retrospective, multicenter cohort study, we included all adult patients diagnosed with heart failure with reduced ejection fraction (HFrEF) within a tertiary healthcare system in Saudi Arabia between January 2018 and December 2021 and were initiated on Sac/Val. The primary objective was to compare the patient characteristics of those initiating Sac/Val treatment with the participants in the PARADIGM-HF trial. The secondary endpoints included the initiation setting, dose initiation, and titration, as well as alterations in B-type natriuretic peptide and ejection fraction at the 6-month mark. Furthermore, we reported the hospitalization and mortality event rates at the 12-month time point. The study included 400 patients with HFrEF receiving Sac/Val. Compared with the PARADIGM-HF trial, the cohort had a younger mean age and a higher prevalence of diabetes mellitus. SAC/VAL was prescribed as the initial therapy for 34% of the patients, while the remaining participants were initially treated with either an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker before transitioning to Sac/Val. Approximately 75% of patients were initiated on 100 mg Sac/Val twice daily, and 90% initiated therapy in the inpatient setting. The mean ejection fraction significantly improved from 26.5 ± 8.4% to 30.5 ± 6.4% at 6 months (P < .001), while the median B-type natriuretic peptide level change was not significant (P = .39). Our study revealed notable disparities in the baseline characteristics of patients with HFrEF compared with those in the PARADIGM-HF trial. These findings offer valuable real-world insights into the prescription patterns and outcomes of Sac/Val in patients with HFrEF in Saudi Arabia, an aspect not previously represented in the PARADIGM-HF study.

show abstract

“…This is important considering that lower health-related quality of life predicts mortality and re-hospitalization in HF regardless of symptoms severity and LV dysfunction [ 10 ]. This was reflected among Saudi HF patients among whom impaired quality of life was reported [ 11 ] and involvement in a structured management program for HF improved quality of life, reduced mortality as well as hospitalization [ 12 , 13 ]).…”

Section: Introductionmentioning

confidence: 99%

NHC/ SHA 2023 Focused update of the 2019 guidelines for the management of heart failure

Al Habeeb,

Tash,

Elasfar

et al. 2023

Journal of the Saudi Heart Association

View full text Add to dashboard Cite

Background The burden of cardiovascular diseases is undeniable in local populations, who have high mortality rates and a young age of disease onset. A systematic review of emerging evidence and update of the Saudi Heart Association (SHA) 2019 heart failure (HF) guidelines was therefore undertaken. Methodology A panel of expert cardiologists reviewed recommendations of the 2019 guidelines following the Saudi Heart Association methodology for guideline recommendations. When needed, the panel provided updated and new recommendations endorsed by the national heart council that are appropriate for clinical practice and local resources in Saudi Arabia. Recommendations and conclusion The focused update describes the appropriate use of clinical assessment as well as invasive and non-invasive modalities for the classification and diagnosis of HF. The prevention of HF was emphasized by expanding on both primary and secondary prevention approaches. Pharmacological treatment of HF was supplemented with recommendations on newer therapies, such as SGLT-2 inhibitors. Recommendations were also provided on the management of patients with cardiovascular and non-cardiovascular co-morbidities, with a focus on cardio-oncology and pregnancy. Updated clinical algorithms were included in support of HF management in both the acute and chronic settings. The implementation of this focused update on HF management in clinical practice is expected to lead to improved patient outcomes by providing evidence-based comprehensive guidance for practitioners in Saudi Arabia.

show abstract

Assessment of health-related quality of life in patients with heart failure: a cross-sectional study in Saudi Arabia

Cited by 17 publications

References 52 publications

Assessment of Health-Related Quality of Life in Patients with Chronic Heart Failure: A Cross-Sectional Study in Vietnam

Assessment of Health-Related Quality of Life in Patients with Chronic Heart Failure: A Cross-Sectional Study in Vietnam

Real-world analysis of integration of sacubitril/valsartan into clinical practice in Saudi Arabia

NHC/ SHA 2023 Focused update of the 2019 guidelines for the management of heart failure

Contact Info

Product

Resources

About